BWV BLUE WATER VACCINES INC

Blue Water Vaccines to Present at the JMP Securities Life Science Conference

Blue Water Vaccines to Present at the JMP Securities Life Science Conference

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Joseph Hernandez, Chairman and Chief Executive Officer of BWV, will present at the JMP Securities Life Science Conference. Mr. Hernandez will present a corporate overview and update for BWV’s vaccine candidate pipeline.

Session details are as follows:

Date:Wednesday, June 15, 2022
Time:11:30am Eastern Daylight Time (EDT)
Title:Blue Water Vaccines Company Presentation
BWV Participant:Joseph Hernandez, Chairman and Chief Executive Officer

“We are honored to share our company mission and progress with such an esteemed group of investors and colleagues in the biotechnology space,” said Hernandez. “We have had several exciting updates throughout the year, including corporate updates to financing, agreements with collaborators, as well as data releases for our vaccine candidates and look forward to sharing these with all in attendance.”

BWV’s management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting at   or contact BWV at (513) 620-4101.

About Blue Water Vaccines

Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on BWV’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022, and periodic reports filed with the SEC on or after the date thereof. All of BWV’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact Information:

Investor Relations

Email:

Media Contact Information:

Media Relations

513-620-4101

Email:



EN
06/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BLUE WATER VACCINES INC

 PRESS RELEASE

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Aji...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and patients in oncology, today announced the appointment of Ajit Singh, Ph.D. and Thomas Meier, Ph.D. to its Board of Directors. “We are thrilled to announce the addition of Dr. Singh and Dr. Meier to the Board of Direct...

 PRESS RELEASE

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter ...

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shif...

 PRESS RELEASE

Blue Water Biotech Acquires Proteomedix as Part of Transformation to C...

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™ Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a t...

 PRESS RELEASE

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercia...

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the “Proposed Transaction”). This latest announcement is part of the Company’s new business strategy focusing ...

 PRESS RELEASE

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Li...

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1) CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule"). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Form...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch